BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allografts, announced that its management will present at the 16th Annual LD Micro Invitational in Los Angeles, California. The presentation is scheduled for Monday, May 18, 2026, at 1:30 PM ET. Interested parties can access live and archived webcasts on the investors section of the company's website at ir.biostemtechnologies.com.
The LD Micro Invitational is a key event for small-cap and micro-cap companies, providing a platform to showcase their business to investors. For BioStem, this presentation offers an opportunity to highlight its proprietary technologies, including BioRetain®, CryoTek®, and SteriTek®, which are designed to preserve the natural properties of perinatal tissues for clinical use. The company's allografts are used across various medical specialties, and its portfolio includes brands such as Neox®, Clarix®, VENDAJE®, and American Amnion™.
BioStem's participation underscores its commitment to advancing regenerative medicine. The company's quality management system is accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). With a growing product portfolio, expanding clinical research, and a national commercial footprint, BioStem is positioned to impact the regenerative medicine industry.
For investors, this presentation could provide insights into the company's strategic direction and recent developments. BioStem is publicly traded on the OTC market under the ticker BSEM. The latest news and updates regarding the company are available in its newsroom at https://tinyurl.com/bsemnewsroom.
The LD Micro Invitational is known for attracting a diverse audience of investors, analysts, and industry professionals. BioStem's management will likely discuss its market strategies, product pipeline, and financial outlook. This event could be a catalyst for increased visibility and investor interest in the company.
BioStem's presentation at the conference highlights the growing interest in regenerative medicine and the potential of perinatal tissue allografts. As the company continues to expand its clinical initiatives and commercial reach, its appearance at the LD Micro Invitational may signal further growth and innovation in the field.
